Thank you for claiming your business. Kindly check your Email for verification mail from Sulekha.com Our team will contact you shortly!.
About RAbD Biotech
RAbD is a new biotechnology company founded by Gregory Adams, Ph.D., Matthew Robinson, Ph.D. and Roland Dunbrack, Ph.D. that is focused on the knowledge-based design of antibodies that bind to key functional, often highly conserved and difficult to target epitopes. We are using homology modeling, crystal structures, protein docking and design software and algorithms to drive combinatorial sampling of CDRs to computationally design new antibodies and then express, validate and perform further design in an iterative manner. RAbD is currently engaged in a sponsored research agreement for a biotechnology company to re-engineer a promising antibody that can not be developed clinically due to poor stability and eek expression properties. We are seeking venture capital funds to further operationalize RAbD and further develop our own pipeline agents for the treatment of cancer. Specialties Drug Development, Antibody Engineering, Molecular Modeling, Rational Drug Design, Pharmaceuticals, Immuno